All In Biotech

Drug Trial Radar · NCT00097695

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema

Last checked: Nov 20, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

84

Actual

Start

Dec 28, 2004

Primary completion

Jul 17, 2006

Study completion Jul 17, 2006

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Nov 29, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of Icatibant, a bradykinin antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with hereditary angioedema (HAE).

Conditions

  • Angioedema

Interventions

  • IcatibantDrug

    30 mg (3mL) subcutaneous icatibant injection in the abdominal region

  • PlaceboDrug

    Solution for injection, matched to study drug Single dose: 3 mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Onset of Symptom Relief (TOSR)Time frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Georgetown University Hospital, Lombardi Cancer Center

    Washington D.C., District of Columbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.